02 2024.04

RemeGen's Telitacicept Granted Fast Track Designation by US FDA for Treatment of Primary Sjögren's Syndrome Following Permission of the Phase 3 Multicenter Global Clinical Trial

10 2024.03

RemeGen Gives Oral Presentation on Phase 2 Clinical Study Data of Disitamab Vedotin for Cervical Cancer at ESGO 2024

10 2024.01

JPM Healthcare Conference 2024|Dr. Fang Jianmin’s Speech: Promote the Global Development of Telitacicept at Full Speed and Create a Pioneer Blockbuster Drug in the Field of B Cell-mediated Autoimmunity

08 2024.01

RemeGen’s ADC RC88 Targeting MSLN in Patients with Ovarian Cancer and Other Tumors Obtained FDA Fast Track Designation

25 2023.12

Annals of the Rheumatic Diseases, the Top International Rheumatology Journal, Published the Study Results of Telitacicept in the Treatment of Active Systemic Lupus Erythematosus

19 2023.12

FDA Grants IND Approval to RemeGen’s RC88 Targeting MSLN for Phase 2 Ovarian Cancer Treatment

22 2023.11

JCO, a Top Oncology Journal, Published Research Results of Disitamab Vedotin of RemeGen in the Treatment of Urothelial Cancer

22 2023.11

RemeGen’s Telitacicept Granted Full Approval by NMPA

26 2023.10

IOSCO World Investor Week Campaign Implementation Plan

16 2023.02

RemeGen Disitamab Vedotin in Combination with Pyrotinib Maleate Tablets in the Treatment of Non-Small Cell Lung Cancer Approved for Clinical Trials